In the CY 2023 OPPS/ASC final rule with comment period (87 FR 71894 through 71895), we updated the device descriptor for C1831, effective January 1, 2023, to include the posterior/transforaminal approach at the request of the applicant
For CY 2026, except where otherwise indicated, we proposed to continue our policy and use the costs derived from CY 2024 claims data to set the proposed CY 2026 payment rates for brachytherapy sources because we proposed to use CY 2024 data to set the proposed payment rates for most other items and services that would be paid under the CY 2026 OPPS
Several commenters recommended a lookback period of at least 18 months
Age, certain medications, stomach conditions, and plant-based diets can all interfere with absorption
It is natural for any patient to be worried about scarring from a facelift
Regular use is generally safe, but your healthcare provider may recommend monitoring your levels over time